Phase I/II gene transfer clinical trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA
Phase of Trial: Phase I/II
Latest Information Update: 21 Oct 2019
Price : $35 *
At a glance
- Drugs ABO 102 (Primary)
- Indications Mucopolysaccharidosis III
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms Transpher A
- Sponsors Abeona therapeutics
- 21 Oct 2019 According to an Abeona therapeutics media release, data from this trial will be presented at the 27th European Society of Gene and Cell Therapy (ESGCT) Congress.
- 03 Sep 2019 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 03 Sep 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2022.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History